Adicet Bio Total Liabilities 2017-2025 | ACET

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Adicet Bio total liabilities from 2017 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

Prices Financials Revenue & Profit Assets & Liabilities Margins Price Ratios Other Ratios Other Metrics

Total Assets Cash on Hand Long Term Debt Total Liabilities

Adicet Bio total liabilities from 2017 to 2025. Total liabilities can be defined as the total value of all possible claims against the corporation.

Related Stocks
Company Name	Market Cap
AstraZeneca (AZN)	$218.1B
Amgen (AMGN)	$157.3B
Gilead Sciences (GILD)	$135.7B
Vertex Pharmaceuticals (VRTX)	$119.2B
Bristol Myers Squibb (BMY)	$94.5B
CSL (CSLLY)	$78.8B
GSK (GSK)	$77.4B
Regeneron Pharmaceuticals (REGN)	$59.2B
Alnylam Pharmaceuticals (ALNY)	$40.6B
Argenex SE (ARGX)	$34B
BioNTech SE (BNTX)	$26.6B
Royalty Pharma (RPRX)	$20.5B
Insmed (INSM)	$19.5B
Biogen (BIIB)	$18.7B
Illumina (ILMN)	$15.4B
Genmab (GNMSF)	$14.2B
Genmab (GMAB)	$13.6B
Incyte (INCY)	$13.2B
Moderna (MRNA)	$12.2B
Exelixis (EXEL)	$12B
BioMarin Pharmaceutical (BMRN)	$10.9B
Ascendis Pharma (ASND)	$10.7B
QIAGEN (QGEN)	$10.5B
Swedish Orphan Biovitrum (BIOVF)	$10.4B
Exact Sciences (EXAS)	$10B
Verona Pharma American Depositary Share (VRNA)	$8.9B
Blueprint Medicines (BPMC)	$8.4B
Bio-Techne Corp (TECH)	$8.1B
Roivant Sciences (ROIV)	$7.7B
Legend Biotech (LEGN)	$7.3B